UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.022

Sortiert nach

Prevalence of mutations in common tumour types in Northern England and comparable utility of national and international Trial Finders

Journal of cancer research and clinical oncology, 2023-12, Vol.149 (18), p.16355-16363

2023

Volltextzugriff (PDF)

Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Annals of oncology, 2019-10, Vol.30, p.v485-v486

2019

Volltextzugriff (PDF)

MEDIOLA: A phase I/II trial of olaparib (PARP inhibitor) in combination with durvalumab (anti-PD-L1 antibody) in pts with advanced solid tumours - new ovarian cancer cohorts

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii147

2018

Volltextzugriff (PDF)

A phase IIa study of tisotumab vedotin in patients with previously treated recurrent or metastatic cervical cancer: Updated analysis of full cervical expansion cohort

Annals of oncology, 2018-10, Vol.29, p.viii344-viii344

2018

Volltextzugriff (PDF)

Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699

British journal of cancer, 2010-11, Vol.103 (10), p.1588-1596

2010

Volltextzugriff (PDF)

2746 A Phase 2 open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutation

European journal of cancer (1990), 2015-09, Vol.51, p.S545-S545

2015

Volltextzugriff (PDF)

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet (British edition), 2017-10, Vol.390 (10106), p.1949-1961

2017

Volltextzugriff (PDF)

Academic Opportunities within Clinical Oncology Training

Clinical oncology (Royal College of Radiologists (Great Britain)), 2013-07, Vol.25 (7), p.446-446

2013

Volltextzugriff (PDF)

47P Prevalence of mutations in common tumour types in Northern England and utility of Experimental Cancer Medicine Centre (ECMC) CRUK Trial Finder

Annals of oncology, 2022-03, Vol.33, p.S21

2022

Volltextzugriff (PDF)

529MO Phase II study of olaparib plus durvalumab with or without bevacizumab (MEDIOLA): Final analysis of overall survival in patients with non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancer

Annals of oncology, 2022-09, Vol.33, p.S788-S789

2022

Volltextzugriff (PDF)

814MO Phase II study of olaparib (O) plus durvalumab (D) and bevacizumab (B) (MEDIOLA): Initial results in patients (pts) with non-germline BRCA-mutated (non-gBRCAm) platinum sensitive relapsed (PSR) ovarian cancer (OC)

Annals of oncology, 2020-09, Vol.31, p.S615-S616

2020

Volltextzugriff (PDF)

Tisotumab vedotin (TV) in patients with previously treated recurrent or metastatic cervical cancer: Updated safety and efficacy results from the full cervical cohort of the phase II innova TV 201 study (NCT02001623)

Gynecologic oncology, 2019-06, Vol.154, p.11-12

2019

Volltextzugriff (PDF)

991P Treatment-related adverse events (TRAEs) occurring during dostarlimab therapy in the GARNET study

Annals of oncology, 2021-09, Vol.32, p.S845-S846

2021

Volltextzugriff (PDF)

1190PD - Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Annals of oncology, 2019-10, Vol.30, p.v485-v486

2019

Volltextzugriff (PDF)

1190PDPhase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Emerging treatment options for ovarian cancer: focus on rucaparib

International journal of women's health, 2017-01, Vol.9, p.913-924

2017

Volltextzugriff (PDF)

A phase I dose-escalation study of the novel peptide ALM201 in patients (pts) with advanced solid tumours

Annals of oncology, 2017-09, Vol.28, p.v128-v128

2017

Volltextzugriff (PDF)

OA02.05 First-In-Human Phase 1/2 Trial of Anti-AXL Antibody–Drug Conjugate (ADC) Enapotamab Vedotin (EnaV) in Advanced NSCLC

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S209-S209

2019

Volltextzugriff (PDF)

448TiPMEDIOLA: A phase I/II trial of olaparib (PARP inhibitor) in combination with durvalumab (anti-PD-L1 antibody) in pts with advanced solid tumours - new ovarian cancer cohorts

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

245 INVITED PARP inhibitors in cancer treatment

European journal of cancer supplements, 2008, Vol.6 (12), p.80-80

2008

Volltextzugriff (PDF)

An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Gynecologic oncology, 2018-06, Vol.149, p.246-247

2018

Volltextzugriff (PDF)

963PA phase IIa study of tisotumab vedotin in patients with previously treated recurrent or metastatic cervical cancer: Updated analysis of full cervical expansion cohort

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

A phase IIa study of tisotumab vedotin (HuMax®-TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer

Annals of oncology, 2017-09, Vol.28, p.v330-v331

2017

Volltextzugriff (PDF)

453PPHASE 1 STUDY OF THE PARP INHIBITOR E7449 AS A SINGLE AGENT IN PATIENTS WITH ADVANCED SOLID TUMORS OR B-CELL LYMPHOMA

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv151-iv151

2014

Volltextzugriff (PDF)

Phase 1 Study of the Parp Inhibitor E7449 As a Single Agent in Patients with Advanced Solid Tumors or B-Cell Lymphoma

Annals of oncology, 2014-09, Vol.25, p.iv151

2014

Volltextzugriff (PDF)

1 – 25 von 1.022

Suche als RSS-Feed

Aktive Filter

SpracheEnglisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(907)
Mit Volltextzugriff
(897)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(680)
Life Sciences & Biomedicine
(424)
Humans
(285)
Physical Sciences
(191)
Animals
(168)
Female
(152)
Male
(148)
Technology
(120)
Biological And Medical Sciences
(115)
Mice
(95)
Medical Sciences
(83)
Chemistry
(77)
Physics
(77)
Exact Sciences And Technology
(76)
Engineering
(60)
Middle Aged
(60)
Science & Technology - Other Topics
(59)
Aged
(55)
Adult
(53)
Biochemistry & Molecular Biology
(53)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(10)

Menü

Weitere Dienste

Einstellungen

Prevalence of mutations in common tumour types in Northern England and comparable utility of national and international Trial Finders

Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)

MEDIOLA: A phase I/II trial of olaparib (PARP inhibitor) in combination with durvalumab (anti-PD-L1 antibody) in pts with advanced solid tumours - new ovarian cancer cohorts

A phase IIa study of tisotumab vedotin in patients with previously treated recurrent or metastatic cervical cancer: Updated analysis of full cervical expansion cohort

Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699

2746 A Phase 2 open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutation

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

Academic Opportunities within Clinical Oncology Training

47P Prevalence of mutations in common tumour types in Northern England and utility of Experimental Cancer Medicine Centre (ECMC) CRUK Trial Finder

529MO Phase II study of olaparib plus durvalumab with or without bevacizumab (MEDIOLA): Final analysis of overall survival in patients with non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancer

814MO Phase II study of olaparib (O) plus durvalumab (D) and bevacizumab (B) (MEDIOLA): Initial results in patients (pts) with non-germline BRCA-mutated (non-gBRCAm) platinum sensitive relapsed (PSR) ovarian cancer (OC)

Tisotumab vedotin (TV) in patients with previously treated recurrent or metastatic cervical cancer: Updated safety and efficacy results from the full cervical cohort of the phase II innova TV 201 study (NCT02001623)

991P Treatment-related adverse events (TRAEs) occurring during dostarlimab therapy in the GARNET study

1190PD - Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)

1190PDPhase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Emerging treatment options for ovarian cancer: focus on rucaparib

A phase I dose-escalation study of the novel peptide ALM201 in patients (pts) with advanced solid tumours

OA02.05 First-In-Human Phase 1/2 Trial of Anti-AXL Antibody–Drug Conjugate (ADC) Enapotamab Vedotin (EnaV) in Advanced NSCLC

448TiPMEDIOLA: A phase I/II trial of olaparib (PARP inhibitor) in combination with durvalumab (anti-PD-L1 antibody) in pts with advanced solid tumours - new ovarian cancer cohorts

245 INVITED PARP inhibitors in cancer treatment

An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed (PSR) ovarian cancer (OC)

963PA phase IIa study of tisotumab vedotin in patients with previously treated recurrent or metastatic cervical cancer: Updated analysis of full cervical expansion cohort

A phase IIa study of tisotumab vedotin (HuMax®-TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer

453PPHASE 1 STUDY OF THE PARP INHIBITOR E7449 AS A SINGLE AGENT IN PATIENTS WITH ADVANCED SOLID TUMORS OR B-CELL LYMPHOMA

Phase 1 Study of the Parp Inhibitor E7449 As a Single Agent in Patients with Advanced Solid Tumors or B-Cell Lymphoma

Aktive Filter

Suchergebnisse filtern